PFD Week 2016-Debate: Refractory Overactive Bladder Treatment: Onabotulinum Toxin Bladder Injection vs. Interstim Direct Sacral Nerve Stimulation

Debate: Refractory Overactive Bladder Treatment: Onabotulinum Toxin Bladder Injection vs. Interstim Direct Sacral Nerve Stimulation

Back to course

Video Transcription

Video Summary

The video is a debate about the best treatment for refractory overactive bladder. Dr. Sydney Munson serves as the moderator, while Dr. Tony Visco speaks on behalf of onobotulatum toxin (Botox) and Dr. Karen Noblitt speaks on behalf of sacral neuromodulation. The debate discusses the prevalence and economic burden of overactive bladder and compares the efficacy and cost-effectiveness of Botox and sacral neuromodulation. Dr. Visco argues that Botox is superior in reducing incontinence episodes, achieving complete continence, improving quality of life, and being cost-effective. He cites the ABC and Rosetta trials as evidence. On the other hand, Dr. Noblitt argues that sacral neuromodulation restores function, treats multiple pelvic floor disorders, has sustained benefits, and is more cost-effective and durable compared to Botox. She mentions the Insight trial as evidence. The debate includes rebuttals from both participants and highlights the importance of considering patient preferences and long-term treatment goals.

Asset Subtitle

Session Speakers

Meta Tag

Category Urinary Incontinence

Category Education

Category Office Procedures

Keywords

refractory overactive bladder

Botox

sacral neuromodulation

efficacy

cost-effectiveness

patient preferences